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Abstract
Background: We and others have previously demonstrated that treatment with bone marrow derived DC genetically
modified to express IL-4 reduce disease pathology in mouse models of collagen-induced arthritis and delayed-type
hypersensitivity. Moreover, treatment of normoglycemic NOD mice with bone marrow derived DC, genetically modified to
express interleukin 4 (IL-4), reduces the onset of hyperglycemia in a significant number of animals. However, the
mechanism(s) through which DC expressing IL-4 function to prevent autoimmune diabetes and whether this treatment can
reverse disease in pre-diabetic NOD mice are unknown.
Methodology/Principal Findings: DC were generated from the bone marrow of NOD mice and transduced with adenoviral
vectors encoding soluble murine IL-4 (DC/sIL-4), a membrane-bound IL-4 construct, or empty vector control. Female NOD
mice were segregated into normoglycemic (,150mg/dL) and prediabetic groups (between 150 and 250 mg/dL) on the
basis of blood glucose measurements, and randomized for adoptive transfer of 106 DC via a single i.v. injection. A single
injection of DC/sIL-4, when administered to normoglycemic 12-week old NOD mice, significantly reduced the number of
mice that developed diabetes. Furthermore, DC/sIL-4, but not control DC, decreased the number of mice progressing to
diabetes when given to prediabetic NOD mice 12–16 weeks of age. DC/sIL-4 treatment also significantly reduced islet
mononuclear infiltration and increased the expression of FoxP3 in the pancreatic lymph nodes of a subset of treated
animals. Furthermore, DC/sIL-4 treatment altered the antigen-specific Th2:Th1 cytokine profiles as determined by ELISPOT
of splenocytes in treated animals.
Conclusions: Adoptive transfer of DC transduced to express IL-4 into both normoglycemic and prediabetic NOD mice is an
effective treatment for T1D.
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Introduction
Type I diabetes (T1D) is a polygenic autoimmune disease
characterized by destruction of insulin-secreting b-cells in the islets
of Langerhans by a chronic inflammatory infiltrate. In both humans
and the nonobese diabetic (NOD) mouse, destructive insulitis is
predominantly a T-cell mediated phenomenon, but other cells
types, such as NKT cells and antigen presenting cells (APC), also
play important roles in modulating disease onset and progression
[1,2,3]. A combination of factors including a Th1-skewed CD4+
response as well as a deficiency of regulatory T cells are considered
to be important hallmarks of disease progression [1].
A shift in the Th1/Th2 balance of T cell responses towards
characteristic Th1 properties, such as the release of IFN-c, plays
an important role in the initiation and progression of the
inflammatory response in T1D. Conversely, shifting the balance
of CD4+ responses towards a Th2-mediated response has a
therapeutic effect. Delivery of exogenous IL-4, which polarizes T
cell responses towards a Th2 phenotype, has been demonstrated to
be an effective treatment of T1D in murine models. Systemic
administration of recombinant IL-4 in NOD mice increases Th2-
mediated responses in the spleen, thymus and pancreatic islets [4].
Transgenic NOD mice expressing IL-4 in the pancreatic islets are
protected from the development of diabetes. Similarly, we have
reduced onset of hyperglycemia in NOD mice after regulated
delivery of IL-4 to pancreatic b cells in vivo using an adenoasso-
ciated vector (AAV) expressing IL-4 under the control of the
mouse insulin promoter [5]. Furthermore, we and others have
demonstrated that adoptive transfer of dendritic cell (DC)
transduced ex vivo with IL-4-expressing adenoviral and retroviral
vectors traffic to the spleen and pancreatic lymph node of NOD
mice and are capable of preventing diabetes onset [6,7].
DC are APC which play a critical role in the development of
central tolerance and the maintenance of peripheral tolerance by
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presenting foreign- or self-derived antigens in the context of
instructive secondary signals to T cells. Results from both NOD
mice and patients with type 1 diabetes document abnormalities in
DC function such as increased NF-kB activity, decreased
expression of indoleamine-2,3-dioxygenase, and altered costimu-
latory and cytokine secretion profiles [8,9,10,11]. Further, DC are
responsible for the presentation of islet-cell derived antigens to
diabetogenic T cells as well as to regulatory T cell populations
within the pancreas and pancreatic lymph node [12,13,14]. In
addition to genetic modification to express exogenous IL-4, the
therapeutic benefit of other DC modifications, including expres-
sion of galectin-1, treatment with NF-kB-specific oligodeoxyribo-
nucleotide, and antisense oligonucleotide-mediated blockade of
costimulatory molecule expression has been demonstrated
[15,16,17]. A Phase I study testing DC treated with anti-sense
oligonucleotides to reduce expression of co-stimulatory molecules
in type 1 diabetes patients is underway.
In the NOD mouse model, insulitis typically begins around 3–4
weeks of age, and diabetes occurs in 60–80% of female mice between
12–18 weeks of age depending on the housing conditions. The NOD
model has been used to test a large number of potential therapeutic
interventions, many of which have ultimately had little to no clinical
benefit [18]. Althoughmany interventions are successful in preventing
diabetes onset in younger mice, they fail to prevent diabetes in older
NODmice with more advanced insulitis. Therefore, in our studies we
were interested in determining the therapeutic potential of DC in later
stages of disease progression in the NOD mouse.
Here we demonstrate that DC/sIL-4 treatment delays or
prevents diabetes onset in a significant number of 12 week old
normoglycemic mice, induces changes in the balance of Th2 vs
Th1 effector profiles in splenocytes of treated mice, and induces
upregulation of FoxP3 expression in the PLN of a subset of mice.
We further demonstrate that DC/sIL-4 reduce the progression to
overt hyperglycemia when administered to 12–16 week-old
prediabetic NOD mice that already have impaired responses to
glucose challenge. Taken together, our results indicate that DC/
sIL-4 ameliorates islet destruction in late stages of insulitis through
modulation of T cell responses.
Results
Characterization of DC transduced with IL-4-expressing
vectors
We and others have demonstrated previously that bone marrow
derived DC genetically modified to express IL-4 reduce disease
pathology in mouse models of collagen-induced arthritis and
delayed-type hypersensitivity [19,20]. In arthritis and hypersensi-
tivity models, we found that DC and DC-derived exosomes
modified to express either soluble or membrane-bound IL-4 were
equally capable of ameliorating disease, indicating that the delivery
of high levels of IL-4 alone were not the sole driving factor in the
therapeutic effect [20]. To generate DC expressing IL-4, bone
marrow derived DC were transduced with an adenoviral vector
expressing either soluble (sIL-4) or membrane bound IL-4 (mbIL-4).
After transduction, we observed significantly higher levels of IL-4 in
the supernatant of DC/sIL-4 than in the control or membrane IL-4
transduced DC culture conditions (Figure 1A).
To determine if transduction with the adenoviral vectors
resulted in significant differences in DC maturation, we next
examined the phenotype and maturation status of the DC by
FACS. The culturing method results in a population of DC that is
highly CD11c (.70%) and CD11b (.50%) positive (Table S1),
which was then used for adoptive transfer without further
purification. We examined CD40 expression in all four popula-
tions, and find that ,40% of DC were positive for CD40
regardless of whether they were non-transduced or transduced
with any one of the three vectors examined (Table S1). We also
observed that transduction with a control adenoviral vector (DC/
y5) increases surface expression of B7-1, B7-2, and PD-L2, and
decreased the expression of PD-L1 (Figure 1B). DC/mbIL-4
demonstrated a similar pattern of changes in surface costimulatory
molecule expression. However, DC/sIL-4 have decreased expres-
sion of B7-1 compared to the DC/y5 or DC/mbIL-4, with levels
similar to those seen in the non-transduced DC. Although
transduced DC upregulate costimulatory molecules due to
adenoviral infection, the high levels of IL-4 secreted by the DC/
sIL-4 appears to affect the balance of B7 molecules expressed by
the DC. This is consistent with the previous observation that IL-4
regulates cytotoxic CD8+ T cell responses by modulating the levels
of B7-1 and B7-2 on DC [21].
DC expressing soluble IL-4 delay the onset of
hyperglycemia in 12-week-old NOD mice
Female NOD/ShiLTJ mice were screened beginning at 11 weeks
of age for the development of hyperglycemia. Most NOD mice will
develop severe insulitis by 10 weeks of age, and, in our experiments,
a small percentage (,10%) of mice develop overt hyperglycemia by
12 weeks of age [1]. At 12 weeks, mice with blood glucose
measurements ,150 mg/dL were randomized to receive a single
tail vein injection of 106 DC/sIL-4, 106 DC/mbIL-4, 106 DC/y5,
or saline alone. Blood glucose levels of mice were followed weekly
and the percentage of mice developing hyperglycemia is shown in
Figure 2. Treatment with DC/sIL-4 conferred significant protection
(p#0.05 using the log-rank test) with 50% of mice treated with DC/
sIL-4 developing diabetes by 30 weeks as compared to .90% of
saline-treated mice. There was no therapeutic benefit observed in
mice treated with DC/mbIL-4 or DC/y5, which were not
statistically significant from mice treated with saline alone
(p.0.05 for both groups using log-rank test).
Evaluation of insulitis by histological analysis
12-week old normoglycemic mice received a single tail vein
injection of 106 DC/sIL-4, 106 DC/mbIL-4, 106 DC/y5, or
saline alone and sacrificed at 15 weeks of age. Insulitis was
evaluated by histology in order to determine the effect of treatment
with DC/sIL-4 on mononuclear cell infiltration into the islets.
Three weeks following treatment, mice treated with DC/sIL-4 had
sparsely infiltrated islets, with a majority of islets demonstrating no
mononuclear cell infiltration or peri-insulitis (Figure 3A & B). In
contrast, mice treated with DC/y5 had infiltrative insulitis in
slightly greater than half of the islets (Figure 3C & D). Mice
receiving saline alone had infiltrative insulitis in greater than 75%
of all islets examined, with 50% of all islets completely infiltrated
(Figure 3E &F). The insulitis score (Figure 3G) at 15 weeks of age
in DC/sIL-4 recipient mice was lower (1.4560.93) than in mice
receiving DC/y5 (2.5160.95) or saline (3.1960.86) and there was
a statistically significant difference between the insulitis scores of
the DC/sIL-4 treated and saline treated animals (p = 0.024). The
percentage of total intact islets and those with mild peri-insulitis in
the DC/sIL-4 treatment group was 60%, which was twice the
amount seen in the DC/y5 treated group (33.6%) and three times
as many as that seen in the saline treated group (17.7%).
DC/sIL-4 treatment increases IL-4 secretion by
islet-antigen specific T cells
The balance of Th1 and Th2 cytokines is important for the
progression of autoimmune diseases, and in type 1 diabetes, a
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Th1-skewed balance of T cell responses contributed to the
pathogenesis and progression of the disease [22,23,24]. Treatment
with IL-4 has been shown to maintain Th2 CD4+ T cell responses
that inhibit the progression of diabetes. Thus we investigated
whether DC/sIL-4 treatment had a beneficial effect on Th1/Th2
balance [4]. Normoglycemic 12-week-old NOD mice were treated
with 106 DC/sIL-4, 106 DC/mbIL-4, 106 DC/y5, or saline alone
and at 15 weeks of age the frequency of splenic cells secreting IFN-
c or IL-4 in response was assessed by ELISPOT. Insulin,
Gad65206–222, and NIT-1 (a NOD-derived b-cell line) cell lystate
were used to stimulate islet-specific cytokine secretion in the
splenocytes from treated mice. We did not observe significant
changes in the numbers of splenocytes secreting the Th1-
accociated cytokine IFN-c between treatment groups (Figure 4B).
In contrast, splenocytes from DC/sIL-4 treated mice exhibited a
significant increase in the secretion of the Th2-associated cytokine
IL-4 in response to all three antigens tested (Figure 4A). These
results showing significant increases in the ratio of Th2/Th1
specific T cells after treatment with DC/sIL-4 in all three
stimulation conditions demonstrate that administration of DC/
sIL-4 is able to induce changes in Th1/Th2 balance within NOD
mice.
DC/sIL-4 treatment upregulates FoxP3 expression
Three and four weeks following treatment with DC/sIL-4, mice
were sacrificed and splenocytes analyzed by FACS to determine
the proportion of CD4+ CD25+ FoxP3+ regulatory T cells within
the spleen. Cells were analyzed for expression of CD4, and results
are expressed as the ratio of CD4+ CD25+ FoxP3+ to the total
number of CD4+ splenocytes. The results suggest that DC/sIL-4
treatment did not have any effect the levels of FoxP3+ regulatory
T cells within the spleen.
We next examined the relative changes in gene expression in
the pancreatic lymph nodes of mice three weeks after treatment
with DC/sIL-4 or controls. The pancreatic lymph nodes (PLN)
play an important role in the priming of inflammation in type 1
diabetes, and it has been demonstrated in numerous studies that
adoptively transferred DC are capable of homing to both the
spleen and PLN [15,25]. In a recent study comparing the gene
expression profiles of NOD and NOD.B10 mice, it was
demonstrated that NOD mice lose PLN expression of IL-4 over
time compared to their NOD.B10 counterparts [6]. Thus we were
interested in determining if treatment with DC/sIL-4 would result
in corresponding changes in the levels of gene expression when
compared to DC/y5 or saline treated animals. In particular, we
examined the levels of IL-4, IFN-c, and FoxP3 expression in the
PLN and inguinal lymph nodes (ILN) of treated mice by
quantitative real-time PCR (qRT-PCR). The inguinal lymph
nodes were used as a control to ensure that there was not a general
effect of DC-based therapy on gene expression in all lymph nodes.
Indeed, in all of the experiments, the levels of gene expression in
the inguinal lymph nodes of mice were equivalent between groups.
Also, there were no changes in levels of IL-4 or IFN-c expression
within the PLN of treated animals at four weeks post-treatment.
However, we did detect robust upregulation of FoxP3 in the PLN
of half of the DC/sIL-4 treated mice (Figure 5B). This result is
consistent with induction of a regulatory T cell phenotype or
recruitment of regulatory T cells into the local environment.
A single administration of DC/sIL-4 reduces onset of
hyperglycemia in prediabetic mice
Although many interventions prevent the onset of type 1
diabetes in animal models, few are effective when administered
late in the disease process [26]. Therefore, we examined whether
DC/sIL-4 therapy was effective at preventing the onset of
hyperglycemia when administered in the later stages of disease.
12–16 week-old female NOD/ShiLTJ mice were monitored for
the development of prediabetes, defined as repeat random blood
glucose measurement between 150 mg/dL and 250 mg/dL.
Intraperitoneal glucose tolerance testing of prediabetic 14-week-
old mice showed an abnormal response to glucose during
challenge, with higher peak levels of blood glucose compared to
mice in the normoglycemic group (Figure 6A). In addition, at
90 minutes, the blood glucose levels of the prediabetic group had
still not returned to baseline, indicating an advanced state of
insulitis and islet dysfunction.
The prediabetic mice were randomized to receive a single tail
vein injection of 106 DC/sIL-4, 106 DC/y5, or saline alone
immediately after being classified as prediabetic. As shown in
Figure 6B, mice were randomized between groups such that there
were no significant differences in the starting blood glucose
between the groups. Mice were monitored weekly for the onset of
hyperglycemia, and mice treated with DC/sIL-4 maintained
Figure 1. Characterization of DC used for adoptive cellular therapy. DC transduced with adenoviral vectors expressing soluble IL-4 (DC/sIL-
4), membrane-bound IL-4 (DC/mbIL-4), or empty adenoviral vector (DC/y5) were compared to non-transduced DC (DC/Non) A.) After harvest on day
8, 16106 DC were plated per well in OPTI-MEM media a 96-well tissue-culture plate. Following 24 hours of culture, supernatants were analyzed by
ELISA for levels of IL-4 secretion. B.) After harvest on day 8, DC were collected and analyzed by flow cytometry. Plots were based on live DC as
determined by FSC vs. SSC profiles. Thin lines represent the isotype control stained samples, and bold lines represent staining with anti-B7-1, -B7-2, -
PD-L1, or -PD-L2 antibodies, as shown. The percentage of cells in the sample with positive staining is displayed.
doi:10.1371/journal.pone.0011848.g001
Figure 2. Incidence of diabetes in normoglycemic mice
following DC therapy. Mice were screened beginning at 11-weeks
of age, and only mice with blood glucose measurements less than
150 mg/dL were randomized to receive a single tail vein injection of
either 16106 DC/sIL-4, 16106 DC/mbIL-4, 16106 DC/y5, or saline.
Combined results from 3 identical, independent experiments are
shown. * denotes significance of p#0.05 by log rank test of DC/sIL-4
compared to saline-treated group. The p-value of comparisons between
the DC/mbIL-4, DC/y5, and saline-treated groups is greater than 0.05.
doi:10.1371/journal.pone.0011848.g002
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euglycemia or demonstrated a delay in the onset of hyperglycemia
(Figure 6C). As shown in Figure 6D, DC/sIL-4 treatment
significantly reduced the number of mice developing hyperglyce-
mia compared to mice receiving DC/y5 or saline (p#0.05 by
Kaplan-Meier analysis). This result clearly indicates that even in
more advanced stages of disease, DC/sIL-4 treatment can be an
effective therapy to reduce the onset of type 1 diabetes.
Discussion
A large number of interventions are effective at preventing the
onset of diabetes in young NOD mice. However, very few are
effective at preventing the onset of hyperglycemia when admin-
istered after 10 weeks of age or when administered once disease
onset has occurred [18,26]. Similar to previous results, we
demonstrate the ability of IL-4 overexpressing DC to prevent
diabetes onset in the NOD model [6,7]. Our data indicate that
DC/sIL-4 are capable of delaying disease onset (Figure 2) and
reducing mononuclear infiltrate (Figure 3) in normoglycemic, but
insulitic 12-week old mice. Our results are consistent with a recent
report demonstrating that transduction of DC with a lentiviral
vector expressing IL-4 prevents the onset of diabetes in 12-week
old NOD mice [6]. We have extended these initial observations,
now demonstrating that IL-4 transduced DC can prevent the
onset of hyperglycemia in a significant number of prediabetic mice
Figure 3. Mononuclear infiltration in mice following adoptive
DC gene therapy. Normoglycemic mice received a single tail vein
injection of either 16106 DC/sIL-4, 16106 DC/y5, or saline at 12 weeks
of age and were monitored. At 15 weeks of age, mice with normal
blood glucose levels were sacrificed. Photomicrographs were taken of
hematoxylin and eosin stained sections of pancreata collected from
these mice. Mice treated with DC/sIL-4 show little or mild mononuclear
infiltration surrounding the islets (A–B), whereas DC/y5 treated mice
have moderate islet infiltration in the majority of islets (C–D), and the
majority of mice treated with saline have severe insulitis (E–F). G.) The
insulitis score was determined by a blinded investigator using the
following scale: 0 = no lymphocytic infiltration; 1 =peri-insultits; 2 = in-
sulitis affecting less than 33% of the islet area; 3 = insulitis affecting
33%–66% of the islet area; 4 = insluitis affecting greater than 66% of the
islet area. A minimum of 30 islets were evaluated per mouse on a
minimum of 3 slides at least 100 mm apart. Statistical comparison
between the groups using Student’s t-test demonstrates: DC/sIL4 vs.
Saline p = 0.024, DC/sIL/4 vs. DC/y5 p = 0.167, DC/y5 vs. Saline
p = 0.293.
doi:10.1371/journal.pone.0011848.g003
Figure 4. Antigen-specific IL-4 secretion by splenic T cells
following treatment with DC overexpressing IL-4. Normoglyce-
mic mice received a single tail vein injection of either 16106 DC/sIL-4,
16106 DC/y5, or saline at 12 weeks of age and were monitored until 15
weeks of age, when they were sacrificed. Splenocytes were obtained
from mice and assessed by ELISPOT for the frequency of splenic T cells
secreting IL-4 (panel A) or IFN-c (panel B) in response to stimulation
with GAD65206–220, insulin, and NIT-1 cell lysate. Results shown are
representative of four mice per group. Using student’s t-test, ** denotes
significance at p,0.05 of DC/sIL-4 treated group compared to both DC/
y5 and saline treated groups, * denotes significance at p,0.05 of DC/
sIL-4 group compared to saline alone.
doi:10.1371/journal.pone.0011848.g004
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(Figure 6B). Screening NOD mice for elevated blood glucose
allowed us to efficiently select mice with impaired response to
glucose challenge, which is indicative of the most advanced stages
of insulitis (Figure 6A) [27]. Interestingly, our results indicate that
DC/sIL-4 may be more effective at reversing disease onset in the
prediabetic NOD mice (60% diabetes free at 32 weeks of age
compared to 14% of saline-treated mice) than 12-week-old
normoglycemic mice (50% diabetes free at 32 weeks of age
compared to 14% of saline-treated mice). In addition, our results
suggest that at least part of the therapeutic effect of the DC/sIL-4
is mediated through the induction of FoxP3-positive regulatory T
cells.
The therapeutic effect of the DC/sIL-4 in prediabetic NOD
mice was dependent upon their ability to secrete soluble IL-4, as
we do not see any therapeutic benefit in mice receiving the DC/
mbIL-4. This is in contrast to our previous results in arthritis and
hypersensitivity models, where DC/mbIL-4 are equally effective at
reducing inflammation as DC/sIL-4 [20]. The difference between
these model systems and the NOD model of type 1 diabetes
perhaps indicates that the role of the therapeutic DC in this model
is to deliver high levels of IL-4 to critical areas of disease activity,
such as the PLN. As shown by Creusot et al., NOD mice have a
significant reduction of IL-4 levels in their PLN compared to
NOD.B10 controls, and DC transduced to express IL-4 effectively
home to the PLN and correct this deficiency, at least in the short-
term [6]. Our data are consistent with the finding that high levels
of IL-4 secretion are required by the transduced DC in order for a
delay in diabetes onset to be seen.
Use of replication-deficient adenoviral gene vectors to deliver
IL-4 to DC resulted in increased IL-4 expression by DC as well as
an altered DC costimulatory molecule phenotype (Figure 1). Our
data indicate that adenoviral infection results in upregulation of
the costimulatory molecules B7-1, B7-2, and PD-L2, consistent
with other studies evaluating adenoviral gene transfer to DC
[28,29]. We further observed that the high levels of IL-4 secreted
into the culture media result in nearly identical expression levels of
B7-1 on the DC/sIL-4 and non-transduced DC. This is consistent
with a previous report indicating that IL-4 treatment of DC leads
to upregulation of B7-2 and downregulation of B7-1, and that DC
treated with recombinant IL-4 decrease in the activity of
diabetogenic CD8+ cells in a manner dependent on B7-2 on the
DC [21]. Although viral transduction induces changes in
expression of DC costimulatory molecules, we hypothesize that
overexpression of IL-4 mitigates some of these effects, and the
resulting increased B7-2:B7-1 ratio may contribute to the overall
therapeutic effect of the DC/sIL-4 in vivo. Further previous studies
confirm that MHC Class I and II deficient DC transduced to
express soluble IL-4 do not delay diabetes onset, confirming that
there is indeed a critical role for antigen presentation by the
transduced DC for therapeutic effects to be seen [6].
Our analysis of the mechanism of the therapeutic effect of DC/
sIL-4 demonstrated that DC/sIL-4 administration to NOD mice
results in increased islet-antigen specific secretion of the Th2-
cytokine IL-4, whereas there were no changes in the levels of
secreted Th1 cytokine IFN-c (Figure 4). We hypothesize that this
represents an alteration of the T cell responses within the treated
animal, and does not represent persistence of the DC/sIL-4 in vivo
for several reasons. First, ELISPOT assays were conducted three
weeks following the administration of the DC/sIL-4. Previous
studies using DC expressing firefly luciferase as a reporter gene
indicate that DC selectively traffic to the spleen and pancreatic
lymph node of NOD mice and expression of luciferase in these
tissues suggests the numbers of DC peak in these tissues between
day 1 and day 3 and then wane significantly by day 8 post-
injection [6]. Secondly, the frequency of the observed IL-4 spot
forming units in our assays significantly exceeds the original dose
of 106 DC/sIL-4 administered to the mice.
qRT-PCR analysis revealed that FoxP3 was significantly
upregulated in the PLN of half of the mice receiving DC/sIL-4
(Figure 5B). IL-4 has been shown to play a role in the extrathymic
induction of FoxP3+ regulatory T cells [30]. In addition, we have
previously shown that transduction of the islets with an AAV
vector expressing IL-4 under the control of the mouse insulin
promoter results in expansion of the percentage of
CD4+CD25+FoxP3+ regulatory T cells as opposed to saline-
treated control animals [5]. However, splenocytes of DC/sIL-4
Figure 5. Analysis of regulatory T cell induction by DC/sIL-4
treatment. Normoglycemic mice received a single tail vein injection of
either 16106 DC/sIL-4, 16106 DC/y5, or saline at 12 weeks of age and
were monitored until 15 or 16 weeks of age, when they were sacrificed.
A.) Splenocytes were obtained from mice at 15- or 16-weeks of age and
analyzed by FACS for expansion of the CD4+CD25+FoxP3+ regulatory T
cell compartment. Splenocytes were stained using isotype control and
monoclonal antibodies to CD4, CD25 and FoxP3. Gates were set around
live cells using FSC vs. SSC, then around CD4+ cells. Isotype control
staining was used to set the FoxP3 gating, and the number of
CD4+CD25+FoxP3+ cells per sample were collected and are represent-
ed as a ratio over the number of total CD4+ cells counted in each
sample. B.) FoxP3 gene expression from pancreatic (PLN) and inguinal
lymph nodes (ILN) obtained from mice at 15 weeks of age was analyzed
using real-time PCR. Mice had been treated with 16106 DC/sIL-4 (n = 4),
16106 DC/y5 (n = 4), or saline (n = 6) at 12 weeks of age by a single tail
vein injection. Expression of FoxP3 was normalized to the expression of
beta-actin to give the relative expression, and samples from all mice
were then normalized to the mean of the saline-treated ILN group.
doi:10.1371/journal.pone.0011848.g005
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treated mice showed no significant changes in the percentages of
CD4+CD25+FoxP3+ T-cells when compared to control treated
animals either three or four weeks following treatment (Figure 5A).
Thus the induction of regulatory T cells in the PLN may predict
which animals respond positively to DC/sIL-4 therapy.
We previously have demonstrated that exosomes secreted by
DC transduced with IL-4 are therapeutic in mouse models of
delayed-type hypersensitivity and arthritis [20]. Despite a growing
number of studies of exosome-based therapy for autoimmune
disease, there have been no studies exploring the therapeutic
potential of exosomes for type 1 diabetes to date. However, in
contrast to our previous results, in which a dose of 1 mg was
effective at reducing disease when administered systemically by tail
vein in collagen-induced arthritis and experimental autoimmune
encephalomyelitis models [20], 1 mg of DC-derived exosomes was
not capable of delaying the onset of diabetes in NOD mice (data
not shown).
Collectively, our data demonstrate that adoptive transfer of
DC/sIL-4 not only reduces the onset of diabetes in 12-week-old
NOD, but can also maintain euglycemia in prediabetic mice ages
12–16 weeks of age that have demonstrated abnormalities in
glucose homeostasis. This is the first demonstration that DC/sIL-4
are capable of preventing disease onset at such a late stage of
insulitis, and provides further confirmation that this approach is
clinically relevant. A patient’s own DC could be harvested and
modified to express IL-4 ex vivo, then administered via intravenous
Figure 6. Incidence of diabetes in prediabetic mice following DC therapy. Mice were screened beginning at 11-weeks of age, and mice with
blood glucose measurements between 150 and 250 mg/dL were considered prediabetic while mice with blood glucose measurements below
150 mg/dL were considered normoglycemic. A.) Normoglycemic and prediabetic mice were injected with 2mg of L-Dextrose per gram of body
weight, and their blood glucose measurements were measured at 15, 30, 60, and 90 minutes post injection. B.) Mice were randomized into groups in
order to avoid treatment bias based on the initial blood glucose. There were no significant differences in the blood glucose of mice prior to receiving
treatment. By Student t-test: DC/sIL-4 vs DC/Y5 p= 0.703; DC/Y5 vs. Saline p = 0.8937; DC/sIL-4 vs Saline p = 0.8183. C.) Female prediabetic mice
between 12 and 16 weeks of age were randomized to receive a single tail vein injection of either 16106 DC/sIL-4, 16106 DC/y5, or saline, and were
then monitored for the development of hyperglycemia. The results represent the individual responses of each animal treated. D.) Kaplein-Meier
survival analysis was performed to examine differences in response to treatment by group. * denotes significance of p#0.05 by log-rank test of DC/
sIL-4 compared to DC/y5, and saline-treated groups. The p-value of comparisons between the DC/y5 and saline-treated groups is greater than 0.05.
doi:10.1371/journal.pone.0011848.g006
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injection. As identification of patients at risk for type 1 diabetes
improves, it may become increasingly possible to use a cell-based
therapy such as DC/sIL-4 to prevent onset of disease in at risk
individuals, or perhaps to intervene at the time of clinical
diagnosis.
Materials and Methods
Mice
Female NOD/ShiLTJ mice were purchased from Jackson
Laboratory (Bar Harbor, ME) and maintained in a specific
pathogen-free facility at the University of Pittsburgh according to
US Department of Agriculture and National Institutes of Health
guidelines. All experiments were conducted under protocols
reviewed and approved by the Institutional Animal Care and
Use Committee.
Vector construction and Adenovirus Generation
Adenoviruses expressing soluble murine IL-4 (Ad.sIL-4) and
membrane-bound (Ad.mbIL-4) and were constructed, propagated,
and titered according to standard protocols as previously described
[31]. The membrane-bound IL-4 construct is composed of IL-4
fused to the transmembrane domain of CD80. Recombinant
adenoviruses were generated by homologous recombination in
293 cells expressing Cre recombinase (CRE8 cells), after co-
transfection with a plasmid (y5) expressing the adenovirus 5-
derived, E1- and E3-deleted adenoviral backbone and pAdlox, the
adenoviral shuttle vector that expresses either sIL-4 or mbIL-4.
Recombinant adenoviruses were purified by CsCl gradient
ultracentrifugation, dialyzed in sterile virus storage buffer,
aliquoted and stored at 280uC.
DC Generation
BMDC were prepared following a bulk-culture protocol
modified as previously described [32,33]. Briefly, bone marrow
was collected from tibias and femurs of 6- to 7-week-old female
NOD/ShiLTJ mice. Contaminating erythrocytes were lysed, and
monocytes were collected from the interface after centrifuging on
Nycoprep (NycoMed, Roskilde, Denmark) at 6006g for 20 min at
RT. Cells were cultured for 24 h in complete media (RPMI 1640
containing 10% FBS, 50 mM 2-b-Mercaptoethanol, 2 mM
glutamine, 0.1 mM nonessential amino acids, 100 IU/mL peni-
cillin/streptomycin) to remove adherent macrophages. Non-
adherent cells were placed in fresh growth media (complete media
containing 1000 U/mL of GM-CSF and IL-4) to generate DC.
Cells were cultured for 4 days then harvested for adenoviral (Ad)
transduction. For Ad infection, 16106 DC were incubated with
56107 PFU of the virus in 1mL of serum-free media for 2 hours,
and then 10 mL complete media was added to the cells. After
overnight incubation, DC were washed vigorously three times in
PBS to remove excess virus and cultured for an additional 48 h in
growth media. On day 8, DC were recovered and used for
adoptive transfer or in vitro experiments. This infection method
routinely gives us,70–80% transfection efficiency using Ad.eGFP
as a control [34].
FACS Analysis of DC
Dendritic cells were preincubated with anti-CD16/32, then
stained with 1–2 mL of PE-labeled mAbs (B7-1, B7-2, PD-L1, PD-
L2, CD40, CD11b, and CD11c, all from eBioscience, San Diego,
CA) in 100 mL total volume of ice-cold PBS containing goat
serum. Following staining, cells were washed twice in FACS
buffer, resuspended in 400 mL FACS buffer, and examined by
FACS. Results were analyzed using FlowJo (Treestar Inc. Ashland,
OR).
ELISA Analysis of DC Supernatant
Supernatants from DC were collected and analyzed using a
sandwich ELISA to detect IL-4 (eBioscience San Diego, CA)
according to the manufacturer’s protocol. The limits of detection
were 4 pg/mL.
Adoptive Transfer of DC to NOD/ShiLTJ mice
Blood glucose levels of NOD/ShiLTJ mice were monitored
using blood drawn from the tail vein and analyzed via a
glucometer (Ascencia BREEZE; Bayer). Mice with blood glucose
readings below 150 mg/dL were considered normoglycemic. Mice
with repeat measures between 150 and 250 mg/dL on consecutive
days were considered prediabetic, and mice with repeat measures
greater than 300 mg/dL on consecutive days were considered
hyperglycemic.
To test the ability of treatment to delay diabetes onset,
normoglycemic 12-week old female NOD/ShiLTJ mice were
randomized to receive a single tail vein injection with either 106
DC or PBS. For studies examining the ability of DC therapy to
prevent diabetes in prediabetic mice, mice 12–16 weeks of age
with repeat blood glucose measurements between 150 and
250 mg/dL were randomized to receive a single tail vein injection
containing either 106 DC therapy or PBS alone.
Intraperitoneal Glucose Tolerance Test
Mice were fasted for 12 hours, and then weighed. Baseline
blood glucose measurement was determined prior to i.p. injection
with L-Dextrose suspended in PBS at a dose of 2 mg per gram of
body weight. Repeat blood glucose measurements were deter-
mined at 15, 30, 60, and 90 minutes following dextrose injection.
Histology and Islet Grading
Pancreata were collected from 15-week old mice following DC
therapy at 12 weeks of age, and were fixed, and embedded. Only
mice that had remained normoglycemic by 15 weeks of age were
used for histology studies. 5 mm sections were deparaffinized,
stained with hematoxylin and eosin, and evaluated by a blinded
investigator for infiltrating mononuclear cells within the islets.
Individual islets were assigned scores based on their appearance:
0 = no lymphocytic infiltration; 1= peri-insultits; 2 = insulitis
affecting less than 33% of the islet area; 3 = insulitis affecting
33%–66% of the islet area; 4 = insulitis affecting greater than 66%
of the islet area. The histology score index per mouse was
calculated by dividing the sum of all individual islets scored by the
total number of islets evaluated, and was used to represent each
mouse in statistical testing. A minimum of 30 islets were evaluated
per mouse on a minimum of 3 slides at least 100 mm apart.
Evaluation of splenic antigen-specific responses by
ELISPOT and splenic regulatory T cell levels
15-week old mice were sacrificed following DC therapy at 12
weeks of age. Spleens were collected and splenocytes immediately
extracted. Contaminating erythrocytes were lysed with lysis buffer.
For ELISPOT assay, 56105 splenocytes per well were
stimulated with GAD65206–220 (50 ug/mL, Anaspec, Freemont,
CA), insulin (50 ug/mL Sigma-Aldrich, St. Loius, MO), NIT-1
freeze-thaw cell lysate (20 ug/mL), or ovalbumin (OVA) protein
(50 ug/mL Sigma-Aldrich, St. Loius, MO) in serum-free media in
96-well ELISPOT plates precoated with an anti-IL-4 or anti-IFN-
c mAbs. ELISPOT plates were cultured for 36 hours followed by
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incubation with biotin conjugated-anti-IL4 or anti-IFN-c mAb,
and development with streptavidin-peroxidase and 3-amino-9-
ethylcarbazole according to manufacturer’s recommendations (BD
Biosciences, San Jose, CA). Spots were counted with an Immuno-
Spot counter (Cellular Technology, Shaker Heights, OH).
Stimulations were conducted in triplicate per mouse per antigen.
To evaluate levels of splenic T regulatory cells, splenocytes were
surface stained with antibodies for CD4 and CD25 for 30 minutes
at 4uC according to the manufacturer’s recommendations
(eBioscience, San Diego, CA). Cells were washed then incubated
in the dark at 4uC in fixation/permeabilization buffer overnight.
Cells were again washed and resuspended in permeabilization
buffer, and incubated in the dark at 4uC for 1 hr with an anti-
FoxP3 monoclonal antibody (clone FJK-16s, eBioscience). Cells
were washed twice with permeabilization buffer, then resuspended
with FACS buffer and examined by FACS.
Quantitative PCR
15-week old mice were sacrificed following DC therapy at 12
weeks of age. Pancreatic lymph nodes (PLN) were harvested and
RNA isolated according to manufacturer’s recommendations
using an RNAqueous-Micro Isolation Kit (Ambion, Austin TX).
375 ng RNA was used as a template to generate cDNA using
SuperScript III First-Strand Synthesis Kit for qRT-PCR (Invitro-
gen, Carlsbad, CA). Real-time PCR was done using SYBR
GreenER qPCR SuperMix (Invitrogen) kit on an iQ5 device
(Biorad, Hercules, CA). The SuperMix kit uses Fluorescein to
normalize the fluorescence fluctuations between reactions. Primers
used for qRT-PCR were: GACGGCCAGGTCATCACTAT (ß-
actin forward), AAGGAAGGCTGGAAAAGAGC (ß-actin re-
verse), TCTTGCCAAGCTGGAAGACT (FoxP3 forward), GG-
GGTTCAAGGAAGAAGAGG (FoxP3 reverse).
Statistics
Survival analysis was conducted using Kaplan-Meier analysis
and a log-rank test for significance between groups on Stata
statistical software (College Station, TX). Other results were
compared by Student’s t test or ANOVA with Fisher’s Least
Significant Difference post-hoc test using SPSS statistical software
(Chicago, IL). P values#0.05 were considered statistically
significant.
Supporting Information
Table S1 Characteristics of Prediabetic Mouse Experiments.
DC transduced with adenoviral vectors expressing soluble IL-4
(DC/sIL-4), membrane-bound IL-4 (DC/mbIL-4) or empty
adenoviral vector (DC/Y5) were compared to non-transduced
DC (DC/Non). After harvest on day 8, DC were collected and
analyzed by flow cytometry. Gates were set on live DC as
determined by FSC vs. SSC profiles. The percentage of cells in
each sample that was positive for the respective marker above the
baseline isotype control staining is shown in the table. These
results are representative of a single DC preparation.
Found at: doi:10.1371/journal.pone.0011848.s001 (0.13 MB TIF)
Acknowledgments
We would like to thank Joan Nash for her assistance with these studies.
Author Contributions
Conceived and designed the experiments: MAR PDR. Performed the
experiments: MAR. Analyzed the data: MAR PDR. Contributed reagents/
materials/analysis tools: PDR. Wrote the paper: MAR PDR.
References
1. Anderson MS, Bluestone JA (2005) The NOD mouse: a model of immune
dysregulation. Annu Rev Immunol 23: 447–485.
2. Rodacki M, Milech A, de Oliveira JE (2006) NK cells and type 1 diabetes. Clin
Dev Immunol 13: 101–107.
3. Lo J, Clare-Salzler MJ (2006) Dendritic cell subsets and type I diabetes: focus
upon DC-based therapy. Autoimmun Rev 5: 419–423.
4. Cameron MJ, Arreaza GA, Zucker P, Chensue SW, Strieter RM, et al. (1997)
IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese
diabetic mice by potentiation of regulatory T helper-2 cell function. J Immunol
159: 4686–4692.
5. Rehman KK, Trucco M, Wang Z, Xiao X, Robbins PD (2008) AAV8-mediated
gene transfer of interleukin-4 to endogenous beta-cells prevents the onset of
diabetes in NOD mice. Mol Ther 16: 1409–1416.
6. Creusot RJ, Yaghoubi SS, Kodama K, Dang DN, Dang VH, et al. (2008)
Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced
to express IL-4 in NOD mice. Clin Immunol. pp 176–187.
7. Feili-Hariri M, Falkner DH, Gambotto A, Papworth GD, Watkins SC, et al.
(2003) Dendritic cells transduced to express interleukin-4 prevent diabetes in
nonobese diabetic mice with advanced insulitis. Hum Gene Ther. pp 13–23.
8. Angelini F, Del Duca E, Piccinini S, Pacciani V, Rossi P, et al. (2005) Altered
phenotype and function of dendritic cells in children with type 1 diabetes. Clin
Exp Immunol 142: 341–346.
9. Grohmann U, Fallarino F, Bianchi R, Orabona C, Vacca C, et al. (2003) A
defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice.
J Exp Med 198: 153–160.
10. Mollah ZU, Pai S, Moore C, O’Sullivan BJ, Harrison MJ, et al. (2008)
Abnormal NF-kappa B function characterizes human type 1 diabetes dendritic
cells and monocytes. J Immunol 180: 3166–3175.
11. Weaver DJ, Jr., Poligone B, Bui T, Abdel-Motal UM, Baldwin AS, Jr., et al.
(2001) Dendritic cells from nonobese diabetic mice exhibit a defect in NF-kappa
B regulation due to a hyperactive I kappa B kinase. J Immunol 167: 1461–1468.
12. Allen JS, Pang K, Skowera A, Ellis R, Rackham C, et al. (2009) Plasmacytoid
dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and
enhance islet autoantigen presentation to T-cells through immune complex
capture. Diabetes 58: 138–145.
13. Calderon B, Suri A, Miller MJ, Unanue ER (2008) Dendritic cells in islets of
Langerhans constitutively present beta cell-derived peptides bound to their class
II MHC molecules. Proc Natl Acad Sci U S A 105: 6121–6126.
14. Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, et al. (2006) Visualizing
regulatory T cell control of autoimmune responses in nonobese diabetic mice.
Nat Immunol 7: 83–92.
15. Perone MJ, Bertera S, Tawadrous ZS, Shufesky WJ, Piganelli JD, et al. (2006)
Dendritic cells expressing transgenic galectin-1 delay onset of autoimmune
diabetes in mice. J Immunol 177: 5278–5289.
16. Machen J, Harnaha J, Lakomy R, Styche A, Trucco M, et al. (2004) Antisense
oligonucleotides down-regulating costimulation confer diabetes-preventive
properties to nonobese diabetic mouse dendritic cells. J Immunol 173:
4331–4341.
17. Ma L, Qian S, Liang X, Wang L, Woodward JE, et al. (2003) Prevention of
diabetes in NOD mice by administration of dendritic cells deficient in nuclear
transcription factor-kappaB activity. Diabetes 52: 1976–1985.
18. Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, et al. (2005)
A comprehensive review of interventions in the NOD mouse and implications
for translation. Immunity 23: 115–126.
19. Zhong L, Granelli-Piperno A, Choi Y, Steinman RM (1999) Recombinant
adenovirus is an efficient and non-perturbing genetic vector for human dendritic
cells. Eur J Immunol 29: 964–972.
20. Kim SH, Bianco NR, Shufesky WJ, Morelli AE, Robbins PD (2007) Effective
treatment of inflammatory disease models with exosomes derived from dendritic
cells genetically modified to express IL-4. J Immunol 179: 2242–2249.
21. King C, Mueller Hoenger R, Malo Cleary M, Murali-Krishna K, Ahmed R,
et al. (2001) Interleukin-4 acts at the locus of the antigen-presenting dendritic
cell to counter-regulate cytotoxic CD8+ T-cell responses. Nat Med 7:
206–214.
22. Rapoport MJ, Bistritzer T, Aharoni D, Weiss M, Ramot Y, et al. (2005) TH1/
TH2 cytokine secretion of first degree relatives of T1DM patients. Cytokine 30:
219–227.
23. Hill NJ, Van Gunst K, Sarvetnick N (2003) Th1 and Th2 pancreatic
inflammation differentially affects homing of islet-reactive CD4 cells in nonobese
diabetic mice. J Immunol 170: 1649–1658.
24. Papaccio G, Pisanti FA, Montefiano RD, Graziano A, Latronico MV (2002)
Th1 and Th2 cytokines exert regulatory effects upon islet microvascular areas in
the NOD mouse. J Cell Biochem 86: 651–664.
25. Gagnerault MC, Luan JJ, Lotton C, Lepault F (2002) Pancreatic lymph nodes
are required for priming of beta cell reactive T cells in NOD mice. J Exp Med
196: 369–377.
DC.IL-4 Reduce Diabetes Onset
PLoS ONE | www.plosone.org 9 July 2010 | Volume 5 | Issue 7 | e11848
26. Roep BO, Atkinson M, von Herrath M (2004) Satisfaction (not) guaranteed: re-
evaluating the use of animal models of type 1 diabetes. Nat Rev Immunol 4:
989–997.
27. Klueh U, Liu Z, Cho B, Ouyang T, Feldman B, et al. (2006) Continuous glucose
monitoring in normal mice and mice with prediabetes and diabetes. Diabetes
Technol Ther 8: 402–412.
28. Tan PH, Beutelspacher SC, Xue SA, Wang YH, Mitchell P, et al. (2005)
Modulation of human dendritic-cell function following transduction with viral
vectors: implications for gene therapy. Blood 105: 3824–3832.
29. Morelli AE, Larregina AT, Ganster RW, Zahorchak AF, Plowey JM, et al.
(2000) Recombinant adenovirus induces maturation of dendritic cells via an NF-
kappaB-dependent pathway. J Virol 74: 9617–9628.
30. Skapenko A, Kalden JR, Lipsky PE, Schulze-Koops H (2005) The IL-4 receptor
alpha-chain-binding cytokines, IL-4 and IL-13, induce forkhead box P3-
expressing CD25+CD4+ regulatory T cells from CD252CD4+ precursors.
J Immunol 175: 6107–6116.
31. Kim SH, Evans CH, Kim S, Oligino T, Ghivizzani SC, et al. (2000) Gene
therapy for established murine collagen-induced arthritis by local and systemic
adenovirus-mediated delivery of interleukin-4. Arthritis Res 2: 293–302.
32. Son YI, Egawa S, Tatsumi T, Redlinger RE, Jr., Kalinski P, et al. (2002) A novel
bulk-culture method for generating mature dendritic cells from mouse bone
marrow cells. J Immunol Methods 262: 145–157.
33. Bianco NR, Kim SH, Ruffner MA, Robbins PD (2009) Therapeutic effect of
exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-
induced arthritis and delayed-type hypersensitivity disease models. Arthritis
Rheum 60: 380–389.
34. Kim SH, Kim S, Oligino TJ, Robbins PD (2002) Effective treatment of
established mouse collagen-induced arthritis by systemic administration of
dendritic cells genetically modified to express FasL. Mol Ther 6: 584–590.
DC.IL-4 Reduce Diabetes Onset
PLoS ONE | www.plosone.org 10 July 2010 | Volume 5 | Issue 7 | e11848
